Solid Tumor
Solid Tumor - Related Videos
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
0 Views •
Cited by 7 •
2015
In-depth analyses of cancer cell proteomes facilitate identification of novel drug targets and diagnostic biomarkers. We describe an experimental workflow for quantitative analysis of (phospho-)proteomes in cancer cell subpopulations derived from liquid and solid tumors. This is achieved by combining cellular enrichment strategies with quantitative Super-SILAC-based mass spectrometry.
08:50
Predictive Immune Modeling of Solid Tumors
0 Views •
Cited by 4 •
2020
The use of an RNA-based approach to determine quantitative immune profiles of solid tumor tissues and leverage clinical cohorts for immune-oncology biomarker discovery is described through a molecular and informatics protocols.
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
0 Views •
Cited by 8 •
2016
This manuscript describes clinical protocols for two next-generation sequencing panels. One panel interrogates hematologic malignancies while the other panel targets genes commonly mutated in solid tumors. Molecular classification of driver mutations in human malignancies offers valuable prognostic and predictive information.
09:00
Spatial Measurements of Perfusion, Interstitial Fluid Pressure and Liposomes Accumulation in Solid Tumors
0 Views •
Cited by 6 •
2016
The heterogeneous intra-tumoral accumulation of liposomes has been linked to an abnormal tumor microenvironment. Herein methods are presented to measure tumor microcirculation by perfusion imaging and elevated interstitial fluid pressure (IFP) using an image-guided robotic system. Measurements are compared to the intra-tumoral accumulation of liposomes, determined using volumetric micro-CT imaging.
06:26
Analysis of Side Population in Solid Tumor Cell Lines
0 Views •
2021
A convenient, fast, and cost-effective method to measure the proportion of side population cells in solid tumor cell lines is presented.
FAQs
The tumor microenvironment can alter tumor behavior through interactions among cancer cells, stromal cells, blood vessels, and immune cells. These relationships affect how the tumor grows and responds to treatment, so studying cancer cells alone may not capture clinically relevant behavior. Researchers therefore examine the surrounding cellular environment when investigating progression and therapeutic response.
Genetic and regulatory changes can disrupt normal controls on cell division, allowing cancer cells to expand and acquire behaviors associated with progression. Cancer research examines these changes alongside outcomes such as invasion, metastasis, and treatment resistance. Connecting molecular alterations with these behaviors helps researchers investigate how tumors develop and identify mechanisms that may guide therapeutic strategies.
Therapeutic resistance can reflect more than properties of the cancer cells themselves. Interactions with stromal cells, blood vessels, and immune cells shape the tumor microenvironment, which in turn influences treatment response. By examining these relationships, researchers can investigate why a tumor does not respond as expected and search for strategies that address both cancer cells and their surrounding context.
Each research model provides a different way to examine tumor biology. Patient samples preserve features of tumors under study, while cell cultures, organoids, and animal models support controlled investigations of growth, invasion, metastasis, and treatment response. Using several approaches allows researchers to compare findings across experimental settings and build a broader understanding of tumor progression and resistance.
A study may begin with patient samples or an experimental model, followed by analysis of tumor growth, invasion, metastasis, or treatment response. Researchers can compare observations across cell cultures, organoids, and animal models, then relate the findings to tumor microenvironment interactions. This workflow supports investigation of disease mechanisms while providing evidence for biomarker and therapeutic studies.
Studies of solid tumors can support biomarker identification, drug development, and more precise approaches to diagnosis and treatment. Researchers use evidence about tumor progression, microenvironment interactions, metastasis, and therapeutic resistance to determine which biological features may be useful for classification or intervention. These outcomes connect experimental cancer research with strategies designed to improve treatment precision.